Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia

Published:2023-10-23 Issue:14 Volume:64 Page:2286-2295
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Huntington Scott F.¹,de Nigris Enrico²,Puckett Justin³,Kamal-Bahl Sachin³,Farooqui Mohammed²,Ryland Katherine²,Sarpong Eric²,Leng Siyang²,Yang Xiaoqin²,Doshi Jalpa A.⁴

Affiliation:

1. Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA

2. Merck & Co., Inc., Rahway, NJ, USA

3. COVIA Health Solutions, Lansdale, PA, USA

4. Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Funder

Merck Sharp & Dohme Corp.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2256911

Reference24 articles.

1. American Cancer Society. What is chronic lymphocytic leukemia? [cited 2023 Jan 9]. Available from: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/what-is-cll.html

2. Advances in chronic lymphocytic leukemia pharmacotherapy

3. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape

4. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

5. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study